NEW YORK & VERO BEACH, Fla.–(BUSINESS WIRE)–$health #Consumer–NASDAQ IVCP Swiftmerge Acquisition Corp (“Swiftmerge”), a $225 million innovative healthcare investment corporation and a special purpose acquisition company, announced today the signing of a non-binding letter of intent (“LOI”) for a business combination with HDL Therapeutics Inc. (“HDL Therapeutics”), a privately held commercial stage biotech company with … [Read more…]

Company also completes Phase 1 epithelial study to evaluate the safety of topical TTHX1114 to reduce the duration and impact of corneal epithelial defects SAN DIEGO–(BUSINESS WIRE)–Trefoil Therapeutics, a clinical-stage biotechnology company focused on developing novel new therapeutic agents to treat corneal diseases, today announced a series of data presentations demonstrating the potential use of … [Read more…]

NEWPORT BEACH, Calif. & HONOLULU–(BUSINESS WIRE)–National Nephrology Alliance (NNA), a management services organization that partners with nephrology practices to enhance practice growth and align practice groups for value-based care, announced today its strategic alliance with Hawaii Kidney Specialists (HKS), the largest nephrology practice in Hawaii. NNA’s partnership with HKS follows NNA’s recent collaboration with Nephrology … [Read more…]

CINCINNATI–(BUSINESS WIRE)–Chemed Corporation (NYSE: CHE) today announced that it will release financial results for the first quarter ended March 31, 2023, on Wednesday, April 26, 2023, following the close of trading on the New York Stock Exchange. Chemed will host a conference call and webcast at 10 a.m., ET, on Thursday, April 27, 2023, to … [Read more…]

Leading experts and educators will highlight social and emotional wellness and the impacts of trauma on mental health PHOENIX–(BUSINESS WIRE)–University of Phoenix is pleased to announce Dr. Rodney Luster and Dr. Talee Vang as the keynote speakers for the second day of the University’s annual Inclusive Leadership Summit and Career Fair, May 2-4, 2023. The … [Read more…]

SOPHIA-ANTIPOLIS, France–(BUSINESS WIRE)–Regulatory News: Median Technologies (ALMDT:PA) announced today that Fredrik Brag, CEO and Founder of Median Technologies, will provide a company update on May 3rd, 2023 during two webcasts: Webcast held in English: at 4:00 pm CEST / 10:00 am EDT Registration link: https://register.gotowebinar.com/register/7324060688550180191 Webcast held in French: at 6:00 pm CEST / 12:00 … [Read more…]

Expanded testing panel provides a better understanding of a patient’s genetic medication risk profile. Genomind’s real-time, interactive, medication management tool GenMedPro™ has expanded to include over 1,000 medications. This expansion empowers providers to more effectively prescribe medications by easily assessing gene-drug, drug-drug, and drug-environment interactions with the ability to adjust prescriptions based on critical personalized … [Read more…]

LONDON–(BUSINESS WIRE)–#businesstravel–Malaria continues to occur in more than 80 countries, causing over 240 million infections each year, including in business and leisure travellers, and international and domestic employees. The World Health Organization estimates there were 2 million more cases of malaria globally in 2021 compared to 20201. International SOS’ data shows the trend continued in … [Read more…]

LIBERTYVILLE, Ill.–(BUSINESS WIRE)–Valent BioSciences LLC, a global leader in the discovery, development, and commercialization of highly effective, low-risk, environmentally compatible technologies and products for agriculture, public health, and forest health, announces the retirement of President and CEO Ted Melnik, effective July 2023. In addition, Salman Mir, currently Executive Vice President and Chief Operating Officer, has … [Read more…]

Pre-clinical data supports DYV800, a pH modulating agent that targets tumor microenvironment (TME) acidity in solid tumors. DYV800, delivered topically to bypass gastrointestinal absorption challenges, neutralizes the TME acidity that plays a strong role in tumor progression. CAMARILLO, Calif.–(BUSINESS WIRE)–#biotechnology—Dyve Biosciences, Inc. (“Dyve”), a clinical-stage platform biotechnology company with assets in immunology and oncology, today … [Read more…]